ERBB2 and breast carcinoma: Additionally, certain genetic mutations, like the V777L ERBB2 mutation and MutL deficiency—related to mismatch repair system changes—suggest potential responsiveness to anti-HER2 therapies, even in HER2-negative breast cancers.